Dechra Pharmaceuticals

Equities

DPH

GB0009633180

Delayed London S.E. Other stock markets 07:30:00 16/01/2024 GMT			5-day change	1st Jan Change
3,866 ^GBX	-.--%		-.--%	+0.21%

04-11	Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.	CI
04-09	Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director	CI

Dechra Pharmaceuticals : AGM Trading Update

October 18, 2019 at 07:09 am

Friday, 18 October 2019

Dechra^® Pharmaceuticals PLC

(Dechra, Group, Company)

AGM Trading update

The Board of Dechra issues the following update prior to the Annual General Meeting (AGM) which will take place at the Company's offices at 6 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA at 1.00 pm today, Friday 18 October 2019.

The Board remains confident about the Company's prospects for the current financial year. Work continues to resolve the supply issues previously highlighted with many of these having now been mitigated.

No other new trading updates are to be made at the AGM today.

Dechra will announce its interim results for the six month period to 31 December 2019 on 24 February 2020.

Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer	Office: +44 (0) 1606 814 730
Paul Sandland, Acting Chief Financial Officer e-mail:corporate.enquiries@dechra.com	Office: +44 (0) 1606 814 730

TooleyStreet Communications Ltd
Fiona Tooley, Director e-mail:fiona@tooleystreet.com	Mobile: +44 (0) 7785 703 523 Office: +44 (0) 121 309 0099

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

For more information, please visit:www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra 'D' logo are registered trademarks of Dechra Pharmaceuticals PLC.

Forward Looking Statement

This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.

Attachments

Original document
Permalink

Disclaimer

Dechra Pharmaceuticals plc published this content on 18 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 October 2019 06:08:03 UTC

Latest news about Dechra Pharmaceuticals

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.	04-10	CI
Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director	04-09	CI
Dechra Group Holdings Limited Appoints Ian David Page as Director	04-09	CI
Dechra Group Holdings Limited Announces Resignation of Thomas Spicer as Director	04-09	CI
Dechra Group Holdings Limited Announces Resignation of Anthony Santospirito as Director	04-09	CI
Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director	04-09	CI
Stocks slump as Fed rate cut hope dwindles	01-17	AN
Dechra Pharmaceuticals Delists From London Bourse Following Freya Bidco’s Takeover	01-17	MT
EQT's Freya Bidco Completes Dechra Pharmaceuticals Purchase	01-16	MT
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-World Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 (Ex Investment Companies) Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from S&P Global BMI Index	01-16	CI
EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC.	01-15	CI
Persimmon to replace outbound FTSE 100 constituent Dechra	01-12	AN
EMEA Morning Briefing : Markets to Track Fresh Middle East Tensions	01-12	DJ
EU clears Dechra Pharmaceuticals takeover by EQT funds	12-27	AN
EQT's Dechra Takeover to Become Effective in Mid-January 2024	12-27	MT
EQT's Takeover of Dechra Pharmaceuticals Gets EU Antitrust Regulator's Nod	12-22	MT
Inchcape to appoint Jerry Buhlmann to chair board of directors from May	12-14	AN
EQT Secures Australian Nod for Dechra Pharmaceuticals Takeover	11-30	MT
FTSE 100 Ends Down, Falling Behind European Peers	11-29	DJ
Hargreaves Lansdown picks Dechra chair Alison Platt as chair	11-29	AN

Chart Dechra Pharmaceuticals

Duration

Period

More charts

Company Profile

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Sector

More about the company

Income Statement Evolution

More financial data